Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Down - Here's Why

Kestra Medical Technologies logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Kestra shares opened sharply lower, falling from the prior close of $28.29 to $26.14 before recovering to trade around $27.47.
  • The company reported a quarterly loss of $0.75 per share, missing analyst expectations of a $0.61 loss; revenue was $30.97 million.
  • Analyst sentiment remains moderately positive, with a consensus “Moderate Buy” rating and $29 average price target, though one firm downgraded the stock to Sell. Insiders have also sold shares recently.
  • MarketBeat previews top five stocks to own in December.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $28.29, but opened at $26.14. Kestra Medical Technologies shares last traded at $27.4690, with a volume of 17,577 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts have recently commented on KMTS shares. Wall Street Zen downgraded shares of Kestra Medical Technologies from a "hold" rating to a "sell" rating in a report on Sunday, November 8th. Evercore initiated coverage on Kestra Medical Technologies in a research note on Tuesday, October 20th. They issued an "outperform" rating and a $34.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on Kestra Medical Technologies in a research note on Monday, August 10th. They issued an "overweight" rating and a $30.00 target price for the company. Royal Bank Of Canada set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Finally, BTIG Research reissued a "buy" rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.00.

Check Out Our Latest Stock Analysis on Kestra Medical Technologies

Kestra Medical Technologies Stock Performance

The stock has a 50 day simple moving average of $27.63 and a 200 day simple moving average of $24.17. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.59 billion, a P/E ratio of -9.99 and a beta of 0.45.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The firm had revenue of $30.97 million during the quarter. Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. On average, equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current year.

Insiders Place Their Bets

In other Kestra Medical Technologies news, insider Traci Umberger sold 100,000 shares of the business's stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $27.18, for a total transaction of $2,718,000.00. Following the sale, the insider directly owned 195,825 shares of the company's stock, valued at $5,322,523.50. The trade was a 33.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Conor Hanley sold 5,694 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $25.25, for a total value of $143,773.50. Following the completion of the sale, the director directly owned 6,272 shares of the company's stock, valued at approximately $158,368. The trade was a 47.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 251,456 shares of company stock worth $7,173,746. Company insiders own 5.30% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Sterling Capital Management LLC raised its position in Kestra Medical Technologies by 834.0% in the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company's stock valued at $25,000 after buying an additional 784 shares during the last quarter. Global Retirement Partners LLC increased its holdings in shares of Kestra Medical Technologies by 56,300.0% in the third quarter. Global Retirement Partners LLC now owns 1,692 shares of the company's stock worth $48,000 after purchasing an additional 1,689 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Kestra Medical Technologies in the 3rd quarter valued at about $353,000. Pathstone Holdings LLC bought a new position in shares of Kestra Medical Technologies in the 3rd quarter worth $356,000. Finally, Quantinno Capital Management LP purchased a new stake in Kestra Medical Technologies during the first quarter valued at about $431,000.

Kestra Medical Technologies Company Profile

(Get Free Report)

Kestra Medical Technologies is a medical technology company focused on wearable solutions for people at risk of sudden cardiac arrest. Its products combine cardiac monitoring, treatment technology and digital services intended to support patients and their care teams. The company's flagship product, the ASSURE wearable cardioverter defibrillator, continuously monitors a patient's heart rhythm and can deliver a treatment shock if it detects a life-threatening arrhythmia. The system also provides alerts and supports remote sharing of patient data with clinicians.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Kestra Medical Technologies Right Now?

Before you consider Kestra Medical Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.

While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines